Pharmaceuticals News & Press Release Distribution

Taiko Pharmaceutical Officially Launches "Cleverin" in Mexico, Top Made-in-Japan Brand for Removing Viruses/Bacteria, Deodorization

OSAKA, Japan, March 23, 2021 /PRNewswire/ -- Together with a local distribution partner, Torishi S.A. de C.V., Taiko Pharmaceutical Co., Ltd. (hereinafter Taiko), based inOsaka, Japan, has announced the launch of "Cleverin," a top made-in-Japan brand (*1) among products for removing viruses/bacte...

2021-03-23 14:00 4390

CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary

* Marks vaccine's first approval by an European Union member state, following Mexico, Pakistan and China * Continues to boost production capacity to meet increasing demand * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effectiv...

2021-03-23 00:43 4396

Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences' Anti-PD-1

BOSTON and BEIJING, March 22, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injecti...

2021-03-22 22:30 2128

Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages

SINGAPORE, March 22, 2021 /PRNewswire/ -- Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates potential for treating a variety of solid cancers and COVID-19's post-recovery complications, which include heart damage, diabetes and multi-system ...

2021-03-22 21:00 1801

Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages

SINGAPORE, March 22, 2021 /PRNewswire/ -- Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates potential for treating a variety of solid cancers and COVID-19's post-recovery complications, which include heart damage, diabetes and multi-system ...

2021-03-22 21:00 2003

RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland

TEL AVIV, Israel and RALEIGH, N.C., March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib[1] treatment on an...

2021-03-22 19:00 4286

Tavotek Biotherapeutics Announces Completion of Round A1 and A2 Financing with over $20 Million Dollars

LOWER GWYNEDD, Pennsylvania, March 22, 2021 /PRNewswire/ -- Tavotek Biotherapeutics announces it has raised over $20M in Round A1 and Round A2 financing in the preceding two months. YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Ca...

2021-03-22 19:00 1565

Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections

SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-03-22 10:40 4437

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

SHANGHAI and SUZHOU, China, March 22, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2). This study w...

2021-03-22 10:31 5174

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

SHANGHAI and GAITHERSBURG, Md., March 22, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematolog...

2021-03-22 08:00 3551

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

Innoforce Pharmaceuticals Completes 625M CNY ($96M) Series A Financing

HANGZHOU, China, March 22, 2021 /PRNewswire/ -- Innoforce Pharmaceuticals ("INF"), a biopharmaceutical innovation and partnership company, announced today the completion of a625M CNY ($96M) Series A financing, which follows a 170M CNY ($24M) Pre-A financing completed in June 2020. The Series A ...

2021-03-22 08:00 4846

Ocumension Therapeutics (1477.HK) Reports Revenue Growth in 2020, National Commercial Construction has been started to become outstanding

HONG KONG, March 20, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company,Ocumension Therapeutics ("Ocumension" or the "Company", together with its subsidiaries, the "Group" ), (stock code: 1477.HK), announced its annual results for the year ended31 December 2020 today. Ocumension The...

2021-03-20 18:20 9227

Qiming's Portfolio Company Connect Biopharma Lists on Nasdaq

SHANGHAI, March 20, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price isUS$ 17.00/ADS. The stock opened at US$19.55/ADS and closed atUS$18.49/ADS on the first trading day, up 8.8%, with a market...

2021-03-20 09:00 16114

Everest Medicines to Announce Full-Year 2020 Financial Results on March 22, 2021

SHANGHAI, March 19, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced ...

2021-03-19 14:43 5932

WuXi Biologics to Acquire CMAB and Form Strategic Partnership with CBC Group

SUZHOU, China, March 18, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced it has entered into a purchase agreement with CBC Group ("CBC"), a healthcare-dedicated investment firm, and other compani...

2021-03-18 08:59 4060

Merck Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies

DARMSTADT, Germany, March 17, 2021 /PRNewswire/ -- Merck, a leading science and technology company, will add a single-use assembly production unit at its Life Science Center in Molsheim,France. With the € 25 million investment, the company is accelerating its European expansion plans for this key...

2021-03-17 23:40 3729

Merck Accelerates European Expansion Plans for Single-use Products Critical to Manufacturing Vaccines and Lifesaving Therapies

111, Inc. Enters into First-Ever Strategic Partnership with BeiGene

SHANGHAI, March 17, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (Nasdaq: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, announced today it has entered into a strategic cooperation agreem...

2021-03-17 18:50 4959

WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities from Pfizer China

HANGZHOU, China, March 17, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has entered into an equity agreement with Pfizer China ("Pfizer") to acquire its state-of-the-art biologics manu...

2021-03-17 08:45 4629

Transcenta Continues to Push the Boundary of Cell Culture Productivity by Achieving > 6 g/L PER Day Volumetric Productivity in Continuous Perfusion Platform

SUZHOU and HANGZHOU, China, March 16, 2021 /PRNewswire/ -- Transcenta, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced a major breakthrough in its continuous perfusion cell culture p...

2021-03-17 08:00 1811

Market of TCM Lianhua Qingwen Enlarged with Kenya's Approval

SHIJIAZHUANG, China, March 16, 2021 /PRNewswire/ -- In an announcement published by Yiling Pharmaceutical on Tuesday, it is disclosed the enterprise has received the herbal product license for Lianhua Qingwen Capsules from the Pharmacy and Poisons Board of the Ministry of Health ofKenya. Kenya i...

2021-03-16 20:20 2171